Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to take part voluntarily, have signed a consent form, and are able to follow the study requirements.
- People who have been confirmed through a tissue or cell sample to have limited-stage small-cell lung cancer (a specific early stage where the cancer has not spread widely, classified as T1-3, N0-2, M0).
- People between 18 and 75 years of age; there is no restriction based on gender.
- People whose general physical functioning is rated at a level of 0, 1, or 2 on a standard medical scale (ECOG scale), meaning they are able to carry out at least some daily activities (confirm with trial site).
- People whose life expectancy is estimated to be at least 3 months.
- People who have not previously received any anti-cancer treatment specifically for small-cell lung cancer.
- People who have at least one area of cancer that can be measured using standard imaging criteria (RECIST v1.1).
- People whose blood cell counts meet minimum levels before starting treatment: white blood cell count (specifically neutrophils), platelets, and haemoglobin must all be above certain thresholds (confirm exact values with trial site).
- People whose kidneys are working well enough, based on blood or urine tests measuring kidney function.
- People whose liver is working well enough, based on blood tests measuring liver enzymes and bilirubin levels.
- People whose blood clotting function falls within an acceptable range, based on a standard clotting test (INR).
- People who are capable of having children must agree to use contraception during the study.
- People who are physically able to tolerate chemotherapy, immunotherapy, and surgery.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have already received any anti-cancer treatment for small-cell lung cancer, including chemotherapy or radiation therapy directed at the tumour.
- People who have previously been treated with immune checkpoint inhibitor drugs, such as PD-1 or PD-L1 inhibitors.
- People who have a history of interstitial lung disease, non-infectious lung inflammation, pulmonary fibrosis, acute lung disease, or other uncontrolled systemic conditions.
- People who need ongoing systemic antibiotic, antifungal, or antiviral treatment for a severe or active infection, including tuberculosis.
- People who are known to have HIV.
- People who have active hepatitis B or hepatitis C.
- People who have an active autoimmune disease, or a history of an autoimmune disease that could come back.
- People who need to take corticosteroid medicines or other treatments that suppress the immune system on an ongoing basis.
- People who, in the opinion of the study doctor, have other health conditions that could put them at serious risk or affect their ability to complete the study.
- People who have had major surgery in the 4 weeks before starting treatment, or who have a significant recent injury, fracture, or a wound that has not yet healed.
- People who have serious heart conditions, such as severe heart failure, severe chest pain (angina), a heart attack in the past 6 months, or an irregular heartbeat that requires medication.
- People who have other health conditions that make surgery unsafe for them.
- People who have had an allergic reaction to the study drug or any of its ingredients.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8613488787767
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Pathologic Complete Response (pCR) Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.